CA 125 is a cell surface protein often found on ovarian cancer cells and in some normal tissues. It is one of the protein antigens that has been associated with the presence of various cancers, but is most often positive in ovarian cancer. CA 125 concentrations may also be elevated in other types of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease. CA 125 is a useful tumor marker for evaluating therapy and monitoring disease status in ovarian cancer patients. As the levels decrease it is an indication that the therapy or treatment is working. Post-operatively, the CA 125 concentration correlates with tumor bulk and is a prognostic indicator of clinical outcome. It has been reported that patients with levels exceeding 35 U/mL have the highest risk for clinical recurrence. CA 125 is not useful as a screening mechanism because it is elevated in many non-cancerous conditions, although women that are at higher risk due to family history or other reasons are usually tested regularly as a precautionary method.
Measured serially, serum CA 125 concentration typically corresponds with disease progression or regression. The rate of change in CA 125 is also highly prognostic. A rapid decrease in the level of CA 125 indicates a positive response to treatment. Elevated levels of CA 125 after the third course of primary chemotherapy are typically predictive of poor outcomes.
Note: Normal levels do not exclude recurrent malignancy.
<30 U/mL
Enzyme Immunoassay, ELISA
Carcinoembryonic antigen (CEA), CA 15-3, CA 19-9, Follicle Stimulating Hormone, Luteinizing Hormone, HCG, Progesterone, HE4.
1-3 days.
| 86304 |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| C48 | Malignant neoplasm of retroperitoneum and peritoneum |
| C48.0 | Malignant neoplasm of retroperitoneum |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C54 | Malignant neoplasm of corpus uteri |
| C54.0 | Malignant neoplasm of isthmus uteri |
| C54.1 | Malignant neoplasm of endometrium |
| C54.2 | Malignant neoplasm of myometrium |
| C54.3 | Malignant neoplasm of fundus uteri |
| C54.9 | Malignant neoplasm of corpus uteri, unspecified |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C78 | Secondary malignant neoplasm of respiratory and digestive organs |
| C78.0 | Secondary malignant neoplasm of lung |
| C78.00 | Secondary malignant neoplasm of unspecified lung |
| C78.2 | Secondary malignant neoplasm of pleura |
| C78.4 | Secondary malignant neoplasm of small intestine |
| C78.89 | Secondary malignant neoplasm of other digestive organs |
| C79.00 | Secondary malignant neoplasm of unspecified kidney and renal pelvis |
| C79.11 | Secondary malignant neoplasm of bladder |
| C79.2 | Secondary malignant neoplasm of skin |
| C79.31 | Secondary malignant neoplasm of brain |
| C79.49 | Secondary malignant neoplasm of other parts of nervous system |
| C79.51 | Secondary malignant neoplasm of bone |
| C79.52 | Secondary malignant neoplasm of bone marrow |
| C79.6 | Secondary malignant neoplasm of ovary |
| C79.7 | Secondary malignant neoplasm of adrenal gland |
| C79.81 | Secondary malignant neoplasm of breast |
| C79.82 | Secondary malignant neoplasm of genital organs |
| C79.89 | Secondary malignant neoplasm of other specified sites |
| C79.9 | Secondary malignant neoplasm of unspecified site |
| C80 | Malignant neoplasm without specification of site |
| C80.0 | Disseminated malignant neoplasm, unspecified |
| C80.1 | Malignant (primary) neoplasm, unspecified |
| C80.2 | Malignant neoplasm associated with transplanted organ |
| D21 | Other benign neoplasms of connective and other soft tissue |
| D27 | Benign neoplasm of ovary |
| D27.0 | Benign neoplasm of right ovary |
| D27.1 | Benign neoplasm of left ovary |
| D27.9 | Benign neoplasm of unspecified ovary |
| E00 | Congenital iodine-deficiency syndrome |
| E02 | Subclinical iodine-deficiency hypothyroidism |
| E03 | Other hypothyroidism |
| E03.8 | Other specified hypothyroidism |
| E03.9 | Hypothyroidism, unspecified |
| E89.0 | Postprocedural hypothyroidism |
| N80 | Endometriosis |
| N80.0 | Endometriosis of uterus |
| N80.9 | Endometriosis, unspecified |
| N85.02 | Endometrial intraepithelial neoplasia [EIN] |
| R97 | Abnormal tumor markers |
| R97.0 | Elevated carcinoembryonic antigen [CEA] |
| R97.1 | Elevated cancer antigen 125 [CA 125] |
| Z12.73 | Encounter for screening for malignant neoplasm of ovary |
| Z12.8 | Encounter for screening for malignant neoplasm of other sites |
| Z12.89 | Encounter for screening for malignant neoplasm of other sites |
| Z85 | Personal history of malignant neoplasm |
| Z85.07 | Personal history of malignant neoplasm of pancreas |
| Z85.42 | Personal history of malignant neoplasm of other parts of uterus |
| Z85.43 | Personal history of malignant neoplasm of ovary |
| Z85.44 | Personal history of malignant neoplasm of other female genital organs |